Survey of Patient Satisfaction With Ingenol Mebutate Gel Treatment for Actinic Keratosis From a Community Dermatology Practice.
Actinic keratosis (AK) is a condition that can present as a discrete lesion or as areas of confluent lesions. It is generally treated either with cryosurgery or, less frequently, with patient-applied topical medications or photodynamic therapy. Topical therapies can offer benefits over cryosurgery, especially in patients with significant actinic damage. The long durations of topical treatment required and the persistence of associated local skin reactions (LSRs) may deter some patients from adhering to topical therapies and thus affect clinical outcomes. This study describes patient satisfaction with ingenol mebutate treatment for AK in a community dermatology practice in Austin, Texas. Patients were invited to participate in a survey to evaluate their level of satisfaction with the treatment. The patients completed a questionnaire on ease of use, tolerability, appearance of their skin after treatment, and their likelihood of repeat use of ingenol mebutate for AK. Overall, 42 patients completed the questionnaire. The majority of patients had a ≥10-year history of AK, had received prior cryosurgery, and had used topical therapies, most commonly fluorouracil. After treatment with ingenol mebutate, more than 90% of patients reported a good or excellent treatment experience and an improved appearance of their skin. Patients cited the brief 2- to 3-day treatment regimen, high efficacy for clearance of AK, and the rapid resolution of LSRs as factors in their satisfaction with treatment.